Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- SURVEY／Many Patients Still Want Hospital-Based Doctors to Serve as Attending Physicians
September 10, 2007
- Takeda Begins PII Trial for TAK-536 for Hypertension
September 10, 2007
- TOPICS／Pharma Delegates Launches 2007/2008 Season
September 10, 2007
- JCL Bioassay to Start "Cold" MD Studies
September 10, 2007
- Political Science Scholar with Personal
September 10, 2007
- Korosho to Conduct Studies to Introduce CU System
September 3, 2007
- Asian Regulatory Conference to Focus on Multinational Trials, GRP
September 3, 2007
- Korosho Approves 35 New Drugs, New Indications
September 3, 2007
- Industry's Drug Pricing System Reform Proposals Incompatible with Current System: Mr Tsushima
September 3, 2007
- REGULATORY NEWS IN BRIEF
September 3, 2007
- Korosho to Create Council for Promotion of Generics in Each Prefecture
September 3, 2007
- JMA to Survey Medical Professionals' Views on Quality of Generics
September 3, 2007
- Discussions Start for Revision of Ethical GL for Clinical Research
September 3, 2007
- SELF-MEDICATION NEWS IN BRIEF
September 3, 2007
- R&D NEWS IN BRIEF
September 3, 2007
- Daiichi Sankyo Ties Up with Forest Lab. for AZOR
September 3, 2007
- Japan Tissue Engineering's Autologous Epidermis Recommended for Approval
September 3, 2007
- Teijin to Codevelop Ipsen's ITM-077 with Chugai
September 3, 2007
- MEDICAL DEVICE NEWS IN BRIEF
September 3, 2007
- Peptisyntha to Expand Contract Peptide Manufacturing Business in Japan
September 3, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…